Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label Study to Evaluate the Potential Drug-Drug Interaction Between Bemnifosbuvir and Ruzasvir and Food-Drug Interaction in Healthy Adult Subjects

Next Previous
Trial Profile

A Phase 1, Open-Label Study to Evaluate the Potential Drug-Drug Interaction Between Bemnifosbuvir and Ruzasvir and Food-Drug Interaction in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bemnifosbuvir (Primary) ; Ruzasvir (Primary)
  • Indications COVID 2019 infections; Hepatitis C; Liver disorders
  • Focus Pharmacokinetics
  • Sponsors Atea Pharmaceuticals

Most Recent Events

  • 14 Nov 2023 Results assessing pharmacokinetics of Bemnifosbuvir and ruzasvir were presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
  • 13 Nov 2023 Results published in an Atea Pharmaceuticals Media Release.
  • 02 Nov 2023 According to an Atea Pharmaceuticals Media Release, data from this study has been presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2023, being held from November 10-14, 2023 in Boston, MA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top